HUE051151T2 - Glutaminsav-dekarboxiláz (GAD), autoimmun betegség kezelésében történõ alkalmazásra - Google Patents

Glutaminsav-dekarboxiláz (GAD), autoimmun betegség kezelésében történõ alkalmazásra

Info

Publication number: HUE051151T2
Authority: HU; Hungary
Prior art keywords: gad; treatment; glutamic acid; autoimmune disease; acid decarboxylase
Prior art date: 2014-06-04

Application number

HUE15802815A

Other languages

English (en)

Inventor

Anders Essen-Moeller

Johnny Ludvigsson

Original Assignee

Diamyd Medical Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-06-04

Filing date

2015-06-04

Publication date

2021-03-01

2015-06-04 Application filed by Diamyd Medical Ab filed Critical Diamyd Medical Ab

2021-03-01 Publication of HUE051151T2 publication Critical patent/HUE051151T2/hu

Links

208000023275 Autoimmune disease Diseases 0.000 title 1
102000008214 Glutamate decarboxylase Human genes 0.000 title 1
108091022930 Glutamate decarboxylase Proteins 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/44—Antibodies bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/01005—Acetolactate decarboxylase (4.1.1.5)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Mycology (AREA)
Hematology (AREA)
Obesity (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Wood Science & Technology (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Transplantation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

HUE15802815A 2014-06-04 2015-06-04 Glutaminsav-dekarboxiláz (GAD), autoimmun betegség kezelésében történõ alkalmazásra HUE051151T2 (hu)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE1450678		2014-06-04
SE1451315		2014-11-04

Publications (1)

Publication Number	Publication Date
HUE051151T2 true HUE051151T2 (hu)	2021-03-01

Family

ID=54767532

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HUE15802815A HUE051151T2 (hu)	2014-06-04	2015-06-04	Glutaminsav-dekarboxiláz (GAD), autoimmun betegség kezelésében történõ alkalmazásra

Country Status (18)

Country	Link
US (2)	US20170196949A1 (hu)
EP (2)	EP3760224A3 (hu)
JP (2)	JP6686007B2 (hu)
CN (2)	CN114504639A (hu)
AU (3)	AU2015268960B2 (hu)
CA (2)	CA2950893C (hu)
CY (1)	CY1123160T1 (hu)
DK (1)	DK3151853T3 (hu)
ES (1)	ES2807787T3 (hu)
HU (1)	HUE051151T2 (hu)
IL (3)	IL300130B2 (hu)
LT (1)	LT3151853T (hu)
PL (1)	PL3151853T3 (hu)
PT (1)	PT3151853T (hu)
RS (1)	RS60581B1 (hu)
RU (2)	RU2019129803A (hu)
SI (1)	SI3151853T1 (hu)
WO (1)	WO2015187087A2 (hu)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6827113B2 (ja)	2017-01-21	2021-02-10	広州白雲山漢方現代薬業有限公司ＧｕａｎｇｚｈｏｕＨａｎｆａｎｇＰｈａｒｍａｃｅｕｔｉｃａｌＣｏ．，Ｌｔｄ．	シェーグレン症候群の治療におけるペオニフロリン−６’−ｏ−ベンゼンスルホン酸の使用
US20210077587A1 (en) *	2017-09-08	2021-03-18	Diamyd Medical Ab	Genotype stratification in diabetes treatment and prevention
US20210063392A1 (en)	2017-09-08	2021-03-04	Diamyd Medical Ab	Improved immunotherapy
WO2019151939A1 (en) *	2018-02-05	2019-08-08	Diamyd Medical Ab	Novel composition and use thereof
US11752156B2 (en)	2018-03-07	2023-09-12	Athenex HK Innovative Limited	Compositions and methods for treating hyperproliferative skin disorders
US10500217B2 (en)	2018-04-30	2019-12-10	Leslie Ray Matthews, M.D., Llc	Vitamin D3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases
US20220211813A1 (en) *	2019-04-12	2022-07-07	Loma Linda University	Methods for treatment of niemann-pick disease type c
US20240245762A1 (en) *	2021-01-13	2024-07-25	University Of Maryland, College Park	Methods and platforms for promoting antigen-specific tolerance in the treatment of type 1 diabetes and graft rejection and compositions relating thereto
WO2022264088A1 (en) *	2021-06-17	2022-12-22	Phaim Pharma Ltd.	Individualized cell therapy using patient-derived antigen-specific regulatory t cells
WO2023066881A1 (en) *	2021-10-18	2023-04-27	Astrazeneca Ab	Inhibition of map3k15 for treating and preventing diabetes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5674978A (en) *	1990-09-21	1997-10-07	The Regents Of The University Of California	Peptides derived from glutamic acid decarboxylase
JP2000500120A (ja) *	1995-09-21	2000-01-11	ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション	ポリ（エチレングリコール）と抗グルタミン酸デカルボキシラーゼ抗体の結合体の膵島細胞指向ターゲット化
SE9503379D0 (sv) *	1995-09-29	1995-09-29	Synectics Medical Ab	A modified GAD, a method for producing a modified GAD, a method for supplying a modified GAD, a peptide and the use of an ordinary and/or a modified GAD
US6884785B2 (en)	1999-06-17	2005-04-26	The Scripps Research Institute	Compositions and methods for the treatment or prevention of autoimmune diabetes
EP2301553A1 (en) *	2001-11-21	2011-03-30	The Board Of Trustees Of The Leland Stanford Junior University	Polynucleotide therapy
US20050152914A1 (en) *	2003-06-13	2005-07-14	Diamyd, Inc.	Formulation of antigen
EP1725254A4 (en) *	2004-02-04	2008-02-13	Univ Columbia	ANTI-CD3 AND ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF AUTOIMMUNITY
EP1755631A2 (en) *	2004-03-03	2007-02-28	Diamyd Medical AB	Immunomodulation by a therapeutic medication intended for treatment of diabetes and prevention of autoimmune diabetes
WO2007044394A2 (en) *	2005-10-05	2007-04-19	Bayhill Therapeutics, Inc.	Compositions and methods for treatment of autoimmune disease
JP5694668B2 (ja) *	2006-12-29	2015-04-01	ザリージェンツオブザユニバーシティオブコロラド，アボディーコーポレイトＴＨＥＲＥＧＥＮＴＳＯＦＴＨＥＵＮＩＶＥＲＳＩＴＹＯＦＣＯＬＯＲＡＤＯ，ａｂｏｄｙｃｏｒｐｏｒａｔｅ	自己免疫疾患の診断上および治療上の標的ならびにその用途
AU2008240667A1 (en) *	2007-04-24	2008-10-30	Diamyd Therapeutics Ab	Medicaments and methods to treat autoimmune disease and cancer
MX350501B (es) *	2007-10-12	2017-09-07	Massachusetts Inst Technology	Nanotecnologia de vacuna.
EP2219669A4 (en) *	2007-12-19	2011-03-09	Mivac Dev Aktiebolag	COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND ALLERGIC DISEASES
WO2012050907A2 (en) *	2010-09-28	2012-04-19	The Regents Of The University Of California	Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes
WO2012062697A1 (en) *	2010-11-08	2012-05-18	Novartis Ag	Combination therapy for type 1 diabetes
US8735359B2 (en) *	2012-05-24	2014-05-27	Orban Biotech Llc	Combinations of modalities for the treatment of diabetes

2015
- 2015-06-04 RU RU2019129803A patent/RU2019129803A/ru unknown
- 2015-06-04 CA CA2950893A patent/CA2950893C/en active Active
- 2015-06-04 EP EP20172919.1A patent/EP3760224A3/en active Pending
- 2015-06-04 ES ES15802815T patent/ES2807787T3/es active Active
- 2015-06-04 US US15/315,557 patent/US20170196949A1/en not_active Abandoned
- 2015-06-04 RU RU2016150656A patent/RU2702632C2/ru active
- 2015-06-04 DK DK15802815.9T patent/DK3151853T3/da active
- 2015-06-04 JP JP2017516633A patent/JP6686007B2/ja active Active
- 2015-06-04 AU AU2015268960A patent/AU2015268960B2/en active Active
- 2015-06-04 LT LTEP15802815.9T patent/LT3151853T/lt unknown
- 2015-06-04 PT PT158028159T patent/PT3151853T/pt unknown
- 2015-06-04 HU HUE15802815A patent/HUE051151T2/hu unknown
- 2015-06-04 CN CN202210193065.7A patent/CN114504639A/zh active Pending
- 2015-06-04 CN CN201580040912.4A patent/CN106535926B/zh active Active
- 2015-06-04 WO PCT/SE2015/050651 patent/WO2015187087A2/en active Application Filing
- 2015-06-04 PL PL15802815T patent/PL3151853T3/pl unknown
- 2015-06-04 SI SI201531269T patent/SI3151853T1/sl unknown
- 2015-06-04 EP EP15802815.9A patent/EP3151853B1/en active Active
- 2015-06-04 IL IL300130A patent/IL300130B2/en unknown
- 2015-06-04 RS RS20200789A patent/RS60581B1/sr unknown
- 2015-06-04 CA CA3210184A patent/CA3210184A1/en active Pending
2016
- 2016-11-28 IL IL249250A patent/IL249250B/en active IP Right Grant
2020
- 2020-03-12 IL IL273265A patent/IL273265B2/en unknown
- 2020-04-01 JP JP2020066176A patent/JP2020125300A/ja active Pending
- 2020-05-15 AU AU2020203169A patent/AU2020203169B2/en active Active
- 2020-07-28 CY CY20201100694T patent/CY1123160T1/el unknown
2021
- 2021-08-26 US US17/458,018 patent/US20220000995A1/en active Pending
2022
- 2022-03-23 AU AU2022202003A patent/AU2022202003A1/en active Pending

Also Published As

Publication number	Publication date
EP3151853B1 (en)	2020-05-06
AU2020203169B2 (en)	2021-12-23
EP3151853A2 (en)	2017-04-12
EP3151853A4 (en)	2018-04-25
PL3151853T3 (pl)	2020-11-02
US20170196949A1 (en)	2017-07-13
EP3760224A2 (en)	2021-01-06
IL249250A0 (en)	2017-02-28
IL249250B (en)	2020-03-31
AU2015268960B2 (en)	2020-04-09
IL273265B2 (en)	2023-06-01
IL300130B2 (en)	2024-05-01
US20220000995A1 (en)	2022-01-06
LT3151853T (lt)	2020-08-10
CN106535926A (zh)	2017-03-22
IL273265A (en)	2020-04-30
PT3151853T (pt)	2020-07-27
CA2950893A1 (en)	2015-12-10
AU2020203169A1 (en)	2020-06-04
JP2017516870A (ja)	2017-06-22
CA2950893C (en)	2023-10-10
WO2015187087A3 (en)	2016-01-28
JP6686007B2 (ja)	2020-04-22
EP3760224A3 (en)	2021-03-31
WO2015187087A2 (en)	2015-12-10
AU2015268960A1 (en)	2016-12-15
RU2019129803A (ru)	2020-12-14
CY1123160T1 (el)	2021-10-29
ES2807787T3 (es)	2021-02-24
RS60581B1 (sr)	2020-08-31
IL300130A (en)	2023-03-01
DK3151853T3 (da)	2020-07-27
JP2020125300A (ja)	2020-08-20
CA3210184A1 (en)	2015-12-10
RU2702632C2 (ru)	2019-10-09
SI3151853T1 (sl)	2020-10-30
CN106535926B (zh)	2022-02-01
RU2016150656A (ru)	2018-07-10
CN114504639A (zh)	2022-05-17
RU2016150656A3 (hu)	2019-01-25
IL300130B1 (en)	2024-01-01
AU2022202003A1 (en)	2022-04-14

Publication	Publication Date	Title
LT3334422T (lt)	2020-11-25	Kanabidiolio rūgšties panaudojimas epilepsijos gydymui
HUE051151T2 (hu)	2021-03-01	Glutaminsav-dekarboxiláz (GAD), autoimmun betegség kezelésében történõ alkalmazásra
IL283258A (en)	2021-07-29	A preparation for the treatment of hypothyroidism
SG11201704681QA (en)	2017-07-28	Artificial nucleic acid molecules
PL3157512T3 (pl)	2019-02-28	Zastosowanie kannabidioli w leczeniu padaczki
EP3145875A4 (en)	2018-03-07	Electrochemical treatment methods
ZA202001074B (en)	2023-10-25	Inhibitors of a-amino-b-carboxymuconic acid semialdehyde decarboxylase
SI3197472T1 (sl)	2022-01-31	Rekombinantni proteini brez PHE za uporabo pri zdravljenju fenilketonurije
IL251571A0 (en)	2017-06-29	Variable proteins comprising the cry1da1 amino acid sequence are activated by lepidopteran
IL247589A0 (en)	2016-11-30	Dihydropyridine mgat2 inhibitors for use in the treatment of metabolic disorders
PL3277280T3 (pl)	2024-01-22	Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
HK1231388A1 (zh)	2017-12-22	糖代謝改善劑
GB201417163D0 (en)	2014-11-12	Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
HUE039750T2 (hu)	2019-02-28	Hidroxi-buspiron mozgászavarok kezelésére
PL2990398T3 (pl)	2019-06-28	Hydrofilne estry kwasu poliasparginowego
PT3177599T (pt)	2020-03-05	Análogos fumarato e utilizações dos mesmos no tratamento de uma doença autoimune ou uma doença inflamatória
ZA201802201B (en)	2021-07-28	Novel formulation and treatment methods
PL2975004T3 (pl)	2018-01-31	Obróbka kwasowych ścieków
GB201401806D0 (en)	2014-03-19	Novel methods for diagnosis and therapy
ZA201801788B (en)	2019-10-30	Lysobactin for use in the treatment of bovine mastitis
IL247732A0 (en)	2016-11-30	Perinase inhibitory peptides and their use in the treatment of clinical pathologies